Answers are grounded in this paper and cite their sources.
CAP is very efficient to detect even low grade steatosis. CAP being implemented on FibroScan(®) (Echosens, Paris, France), both steatosis and fibrosis can be evaluated simultaneously, enlarging the spectrum of non-invasive techniques for the management of chronic liver diseases.
No takes yet. Share an insight, caveat, or question.
Lédinghen et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: